Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial

  title={Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial},
  author={Yusuke Iwata and Sachiko Irie and Hiroyuki Uchida and Takefumi Suzuki and Koichiro Watanabe and Satoru Iwashita and Masaru Mimura},
  journal={Journal of the Neurological Sciences},

Tables from this paper

Pharmacological treatment of tardive dyskinesia: recent developments
Evidence from Phase III trials of novel vesicular monoamine transporter-2 inhibitors demonstrates they could have a significant effect on TD symptom severity and suggests these agents may have the potential to transform treatment of TD in coming years.
Management of Tardive Syndrome: Medications and Surgical Treatments
  • S. Factor
  • Medicine, Psychology
  • 2020
The discussion will start with switching antipsychotics and the use of clozapine monotherapy which, despite the lack of higher-level evidence, should be considered for the treatment of psychosis and TS.
Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management
An overview of emerging data concerning proposed pathophysiology theories, epidemiology, risk factors, and therapeutic strategies for Tardive dyskinesia is provided.
New and emerging treatments for symptomatic tardive dyskinesia
There is currently no US Food and Drug Administration-approved treatment for tardive dyskinesia; however, prudent use of atypical antipsychotics with routine monitoring remain the cornerstone of therapy, with experimental treatment options available for further management.
Treatment of neurolept-induced tardive dyskinesia
  • S. Jankelowitz
  • Biology, Psychology
    Neuropsychiatric disease and treatment
  • 2013
Tardive dyskinesia includes orobuccolingual movements and “piano-playing” movements of the limbs and therapeutic interventions have attempted to manipulate dopamine, GABA, acetylcholine, norepinephrine and serotonin pathways and receptors.
An Update on Tardive Dyskinesia: From Phenomenology to Treatment
The most current information is provided on the history, nomenclature, etiology, pathophysiology, epidemiology, phenomenology, differential diagnosis, and treatment of tardive dyskinesia.
Tardive dyskinesia (syndrome): Current concept and modern approaches to its management
It is very disappointing to realize that the introduction of antipsychotics from the second generation has not significantly decreased the prevalence and incidence of tardive dyskinesia.
A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia
This study provides Class I evidence that zonisamide improves myoclonus and related disability in patients with myoconus-dystonia and well-tolerated and effective on the motor symptoms of myOClonus- dystonia.


Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.
  • M. Murata
  • Biology, Psychology
    Current pharmaceutical design
  • 2004
It is suggested that the activation of dopamine synthesis and the moderate level of MAOB inhibition are main mechanisms of ZNS effects on PD.
Drug therapies for tardive dyskinesia: Part 1.
  • R. Howland
  • Psychology, Medicine
    Journal of psychosocial nursing and mental health services
  • 2011
Although efficacy evidence for buspirone (Buspar®) in TD is limited, this drug is safe and well tolerated and would be reasonable to try.
Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study.
Vitamin B( 6) appears to be effective in reducing symptoms of TD, and the specific mechanisms by which vitamin B(6) attenuates symptoms ofTD are not clear.
Zonisamide: review of its use in epilepsy therapy.
Zonisamide is considered as a drug that effectively reduces the frequency of partial seizures and has a good pharmacokinetic profile and a low drug interaction potential.
Tardive dyskinesia and essential fatty acids
Tardive dyskinesia is a movement disorder described in individuals who have been treated with anti-dopaminergic agents and large multi-centre studies with sound methodology of both EFAs and antioxidants are needed.
The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study.
  • J. de Leon
  • Psychology, Medicine
    European archives of psychiatry and clinical neuroscience
  • 2007
This study raises the question that new TD studies need to establish whether decades of treatment with atypical antipsychotics make a difference, and the lack of information on the duration of the atypicals and their relatively recent introduction to the market.
Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives.
Induction of free radicals by neuroleptic drugs leading to the oxidative stress and resultant structural abnormality could be the key factor in the pathogenesis of tardive dyskinesia.
Oxidative Mechanisms and Tardive Dyskinesia
Because evidence has continued to accumulate for increased oxidative damage from antipsychotic medications, but less so for the effectiveness of vitamin E, especially in cases of long-standing tardive dyskinesia, alternative antioxidant approaches to the condition may be warranted.
The effect of atypical versus typical antipsychotics on tardive dyskinesia
  • J. Leon
  • Psychology, Medicine
    European Archives of Psychiatry and Clinical Neuroscience
  • 2006
This study raises the question that new TD studies need to establish whether decades of treatment with atypical antipsychotics make a difference, and naturalistic design, relatively small samples in the first two groups, and lack of information on the duration of the atypicals.
Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety.
ZNS has a broad label for use in Japan, while the regulatory bodies in the USA and Europe have approved it for use only as an adjunctive therapy for partial seizures in adults and it is well tolerated in long-term use.